{"name":"Qingdao Sino-Cell Biomedicine Co., Ltd.","slug":"qingdao-sino-cell-biomedicine-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Infusion of HS-IT101 Injection","genericName":"Infusion of HS-IT101 Injection","slug":"infusion-of-hs-it101-injection","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Lymphodepletion Conditioning","genericName":"Lymphodepletion Conditioning","slug":"lymphodepletion-conditioning","indication":"Autologous hematopoietic stem cell transplantation for multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Infusion of HS-IT101 Injection","genericName":"Infusion of HS-IT101 Injection","slug":"infusion-of-hs-it101-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lymphodepletion Conditioning","genericName":"Lymphodepletion Conditioning","slug":"lymphodepletion-conditioning","phase":"phase_2","mechanism":"Lymphodepletion conditioning involves the use of chemotherapy or radiation to deplete the immune system, making it more receptive to stem cell or bone marrow transplants.","indications":["Autologous hematopoietic stem cell transplantation for multiple myeloma","Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}